Subcortical volumetric alterations as potential predictors of methylphenidate treatment response in youth with attention-deficit/hyperactivity disorder

被引:4
|
作者
Kim, Ji-Sahn [1 ]
Lee, Kyung Hwa [2 ]
Hwang, Chan-Sop [1 ]
Kim, Jae-Won [2 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Psychiat, Seoul, South Korea
来源
JOURNAL OF PSYCHIATRY & NEUROSCIENCE | 2022年 / 47卷 / 01期
基金
新加坡国家研究基金会;
关键词
FUNCTIONAL CONNECTIVITY; TREATMENT-NAIVE; WORKING-MEMORY; ADHD; CHILDREN; HYPERACTIVITY; DEFICIT; DOPAMINE; SEGMENTATION; ADOLESCENTS;
D O I
10.1503/jpn.210074
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Patients with attention-deficit/hyperactivity disorder (ADHD) show structural alterations in the subcortical and dopaminergic regions of the brain. Methylphenidate is a first-line treatment for ADHD, and it is known to affect the subcortical and dopaminergic systems. The degree of pretreatment structural alterations in patients with ADHD may be an important factor in predicting methylphenidate treatment outcomes. The present study examined whether pretreatment volumetric alterations in the subcortical and dopaminergic regions predicted treatment response in youth with ADHD. Methods: This study included 67 youth with ADHD and 25 healthy controls. Youth with ADHD received 8 weeks of methylphenidate treatment. They completed baseline (pretreatment) T-1-weighted structural MRI scans and underwent clinical assessments before and after methylphenidate treatment. The healthy controls also completed baseline structural MRI scans. We assessed volumetric alterations using relative volumes (volume of each region of interest/intracranial volume). Results: Among 67 youth with ADHD, 44 were treatment responders and 23 were nonresponders based on post-treatment scores on the Clinical Global Impression Scale-Improvement. Nonresponders had larger volumes in the bilateral amygdala and right thalamus than responders. Nonresponders also had larger volumes in amygdalar subregions (i.e., the bilateral lateral nucleus and right basal nucleus) and hippocampal subregions (i.e., the right hippocampal head and right molecular layer) relative to responders. Limitations: We did not collect post-treatment structural T-1-weighted images, so volumetric changes related to methylphenidate treatment in youth with ADHD were undetermined. Conclusion: These findings suggest that pretreatment volumetric alterations in subcortical regions may serve as biomarkers for predicting methylphenidate treatment response in youth with ADHD.
引用
收藏
页码:E11 / E20
页数:10
相关论文
共 50 条
  • [1] Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder
    Arns, Martijn
    Vollebregt, Madelon A.
    Palmer, Donna
    Spooner, Chris
    Gordon, Evian
    Kohn, Michael
    Clarke, Simon
    Elliott, Glen R.
    Buitelaar, Jan K.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (08) : 881 - 891
  • [2] Electroencephalographic measures as predictors of methylphenidate response in attention-deficit/hyperactivity disorder
    Wester, A. E.
    Bocker, K. B. E.
    Van Engeland, H.
    Kenemans, J. L.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S83 - S83
  • [3] Pharmacogenetic Predictors of Methylphenidate Dose-Response in Attention-Deficit/Hyperactivity Disorder
    Froehlich, Tanya E.
    Epstein, Jeffery N.
    Nick, Todd G.
    Castro, Maria S. Melguizo
    Stein, Mark A.
    Brinkman, William B.
    Graham, Amanda J.
    Langberg, Joshua M.
    Kahn, Robert S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2011, 50 (11): : 1129 - 1139
  • [4] Response to methylphenidate in boys with attention-deficit hyperactivity disorder
    Zeiner, P
    Bryhn, G
    Bjercke, C
    Truyen, K
    Strand, G
    [J]. ACTA PAEDIATRICA, 1999, 88 (03): : 298 - 303
  • [5] Methylphenidate for Attention-Deficit/Hyperactivity Disorder
    Romanos, Marcel
    Reif, Andreas
    Banaschewski, Tobias
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (09): : 994 - 995
  • [6] Methylphenidate and attention-deficit hyperactivity disorder
    Mellis, Craig
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2016, 52 (03) : 354 - 355
  • [7] Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder
    Vitiello, B
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2001, 165 (11) : 1505 - 1506
  • [8] Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder
    Marcus, SC
    Wan, GJ
    Kemner, JE
    Olfson, M
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2005, 159 (06): : 572 - 578
  • [9] Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder
    Pagerols, M.
    Richarte, V.
    Sanchez-Mora, C.
    Garcia-Martinez, I.
    Corrales, M.
    Corominas, M.
    Cormand, B.
    Casas, M.
    Ribases, M.
    Ramos-Quiroga, J. A.
    [J]. PHARMACOGENOMICS JOURNAL, 2017, 17 (01): : 98 - 104
  • [10] Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder
    M Pagerols
    V Richarte
    C Sánchez-Mora
    I Garcia-Martínez
    M Corrales
    M Corominas
    B Cormand
    M Casas
    M Ribasés
    J A Ramos-Quiroga
    [J]. The Pharmacogenomics Journal, 2017, 17 : 98 - 104